Top Page
Australian Clinical Labs Ltd
(Sydney:ACL)
Australian Clinical Labs Ltd (ACL) vs. iShares MSCI Australia ETF (EWA)
Australian Clinical Labs Ltd Business Overview & Revenue Model
Australian Clinical Labs Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 728.27M | 689.73M | 692.10M | 989.30M | 641.31M | 487.53M |
| Gross Profit | 265.75M | 247.36M | 566.02M | 781.71M | 521.73M | 85.04M |
| EBITDA | 79.99M | 169.65M | 184.93M | 372.75M | 196.67M | 116.30M |
| Net Income | 30.67M | 23.93M | 35.90M | 178.24M | 60.37M | 41.26M |
Balance Sheet | ||||||
| Total Assets | 346.77M | 593.06M | 578.91M | 628.04M | 474.70M | 366.05M |
| Cash, Cash Equivalents and Short-Term Investments | 34.99M | 26.84M | 19.95M | 26.37M | 35.23M | 35.28M |
| Total Debt | 366.84M | 308.90M | 316.32M | 262.38M | 294.26M | 221.21M |
| Total Liabilities | 470.07M | 415.30M | 406.24M | 395.49M | 392.79M | 297.06M |
| Stockholders Equity | -123.30M | 177.53M | 172.42M | 232.44M | 81.90M | 68.99M |
Cash Flow | ||||||
| Free Cash Flow | 160.47M | 153.09M | 136.75M | 262.83M | 144.36M | 92.36M |
| Operating Cash Flow | 167.16M | 159.59M | 143.68M | 284.09M | 153.86M | 101.74M |
| Investing Cash Flow | -111.00K | -7.25M | -12.18M | -72.04M | -6.08M | -9.96M |
| Financing Cash Flow | -171.31M | -146.14M | -137.88M | -220.91M | -147.37M | -60.92M |
Australian Clinical Labs Ltd Technical Analysis
Australian Clinical Labs Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$551.86M | 18.26 | 18.39% | 2.49% | 7.80% | 99.87% | |
52 Neutral | $7.50B | 0.31 | -61.87% | 2.27% | 17.10% | 1.59% | |
| €288.61M | ― | -4.46% | ― | ― | ― | ||
73 Outperform | AU$13.27B | 23.57 | 6.86% | 3.28% | 10.15% | 6.20% | |
53 Neutral | AU$942.25M | 104.12 | 1.14% | 1.99% | 7.83% | ― |
Australian Clinical Labs Ltd Corporate Events
Australian Clinical Labs Ltd has announced the appointment of Stephen Roche as a director, effective from June 20, 2025. The announcement indicates that Roche currently holds no relevant interests in securities, suggesting a fresh start in his role, which may impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced the appointment of Stephen Roche as a new independent non-executive director, who will transition to the role of Chair of the Board by August 2025. Roche brings extensive strategic and operational experience from various sectors, including healthcare, retail, and consumer goods, which is expected to strengthen ACL’s board and support its mission of improving patient outcomes through innovative pathology services.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced a change in the substantial holding of its shares, with Mitsubishi UFJ Financial Group, Inc. increasing its voting power from 5.01% to 6.08%. This change in shareholding could impact the company’s governance and strategic decisions, potentially influencing its market position and stakeholder interests.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced a change in the interests of a substantial holder, First Sentier Investors. The change affects the voting power and relevant interests in the company’s shares, with implications for the control and management of voting rights. This development could impact the company’s governance and influence its strategic decisions, as substantial holders play a significant role in shaping corporate policies.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the issuance of unquoted equity securities as part of an employee incentive scheme. This move involves the issuance of service rights and performance rights, which are not intended to be quoted on the ASX, indicating a strategic step to enhance employee engagement and retention.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the issuance and conversion of unquoted equity securities, specifically 59,046 ordinary fully paid shares, as part of its ongoing financial operations. This move reflects the company’s strategic efforts to manage its equity structure, potentially impacting its market positioning and offering implications for its stakeholders.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the issuance and conversion of unquoted equity securities, specifically 15,662 ordinary fully paid shares. This move is part of the company’s ongoing financial management and could impact its capital structure, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced a change in the interests of a substantial holder, Regal Funds Management Pty Ltd and its associates, in the company’s voting securities. This change reflects a shift in the voting power held by Regal Funds Management, which could impact the company’s governance and decision-making processes, potentially influencing its strategic direction and stakeholder interests.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Allan Gray Australia Pty Ltd, an investment manager, has increased its voting power in Australian Clinical Labs Ltd from 9.90% to 10.95%. This change in substantial holding reflects a strategic move by Allan Gray Australia, potentially impacting the company’s governance and influencing its strategic direction.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Allan Gray Australia Pty Ltd, an investment manager, has increased its voting power in Australian Clinical Labs Ltd from 8.79% to 9.90%. This change in substantial holding reflects a strategic move by Allan Gray Australia, potentially impacting the company’s shareholder dynamics and signaling confidence in the company’s market position.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Allan Gray Australia Pty Ltd, a substantial holder in Australian Clinical Labs Limited, has increased its voting power from 7.50% to 8.79% as of May 30, 2025. This change in interest may influence the company’s governance and strategic decisions, potentially impacting stakeholders and the company’s market positioning.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced an update regarding its ongoing on-market buy-back program. The company reported that it bought back a total of 200,000 ordinary fully paid securities on the previous day, adding to a cumulative total of 5,842,629 securities repurchased. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update on its ongoing on-market buy-back program. As of May 29, 2025, the company has repurchased a total of 5,842,629 ordinary fully paid securities, including 150,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. As of the latest notification, the company has repurchased a total of 5,692,629 ordinary fully paid securities, including 250,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the cessation of 750,000 ordinary fully paid securities due to an on-market buy-back, effective May 19, 2025. This move is part of the company’s capital management strategy, potentially impacting its share value and signaling a focus on optimizing shareholder returns.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. The company has repurchased a total of 250,000 ordinary fully paid securities on the previous day, adding to the cumulative total of 5,192,629 securities bought back to date. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. The company reported that it has bought back a total of 4,892,629 securities prior to the previous day and an additional 300,000 securities on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program, revealing that it bought back 300,000 ordinary fully paid securities on the previous day, adding to a total of 4,592,629 securities repurchased before that day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Allan Gray Australia Pty Ltd, acting as an investment manager for various funds, has increased its voting power in Australian Clinical Labs Ltd from 6.49% to 7.50% as of May 12, 2025. This change in substantial holding indicates a growing interest and influence in the company, potentially impacting its governance and strategic decisions.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced a change in the substantial holding of its shares, with Regal Funds Management Pty Limited and its associates now holding a significant interest. This change in voting power indicates a shift in shareholder dynamics, potentially impacting the company’s strategic decisions and market positioning.
Australian Clinical Labs Ltd announced an update on their ongoing share buy-back program, revealing that a total of 4,442,629 ordinary fully paid securities have been bought back to date. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its market positioning and stakeholder interests.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of the latest notification, the company has bought back a total of 4,274,630 securities, with 150,000 purchased on the previous day. This buy-back initiative may impact the company’s stock value and shareholder equity, reflecting a strategic move to manage capital and potentially enhance shareholder returns.
Australian Clinical Labs Ltd has announced an update on its ongoing on-market buy-back program. The company reported that it bought back 146,130 ordinary fully paid securities on the previous day, adding to a total of 3,978,500 securities bought back prior to that. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Ltd has announced a daily update on its ongoing on-market buy-back program. The company has repurchased a total of 3,978,500 ordinary fully paid securities, with 150,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Limited announced the cessation of Michael Thomas Alscher as a director, effective April 30, 2025. Alscher, who held interests in 280,502 ordinary shares through XYZ Services Pty Limited as trustee for the 3C Trust, will no longer be part of the company’s board. This change in directorship might impact the company’s governance and strategic direction, potentially affecting stakeholders and market perception.
Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program, with a total of 3,678,500 ordinary fully paid securities bought back before the previous day and an additional 150,000 securities acquired on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. As of April 29, 2025, the company has repurchased a total of 3,678,500 ordinary fully paid securities, including 224,731 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Limited has announced a significant development involving Mitsubishi UFJ Financial Group, Inc., which has acquired a substantial holding in the company. This acquisition gives Mitsubishi UFJ Financial Group a 5.01% voting power in Australian Clinical Labs, potentially influencing the company’s governance and strategic decisions. The involvement of a major financial entity like Mitsubishi UFJ Financial Group could impact the company’s market positioning and stakeholder interests.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. The company reported that it bought back a total of 21,950 ordinary fully paid securities on the previous day, adding to the cumulative total of 3,431,819 securities repurchased. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Mitsubishi UFJ Financial Group, Inc. has ceased to be a substantial holder in Australian Clinical Labs Limited as of April 24, 2025. This change in shareholding, involving multiple transactions of ordinary shares controlled by Morgan Stanley, could impact the company’s market dynamics and investor relations, reflecting a shift in stakeholder interests.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities, with a total of 3,265,125 securities bought back before the previous day and an additional 166,694 securities acquired on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value, reflecting a proactive approach to optimizing financial performance and market positioning.
Australian Clinical Labs Limited announced the retirement of its board chair, Mr. Michael Alscher, effective April 30, 2025. Mr. Alscher has been with ACL since 2015, and the company expressed gratitude for his leadership. Mr. Mark Haberlin, currently the Chair of ACL’s Audit and Risk Committee, will serve as Interim Chair. This transition is part of ACL’s succession planning to ensure the board’s composition aligns with its strategic goals. The change in leadership is expected to support ACL’s ongoing strategy and operations, potentially impacting its industry positioning and stakeholder relations.
Australian Clinical Labs Ltd has experienced a change in the interests of its substantial holder, involving entities associated with KKR. The KKR Entities have increased their voting power in the company from 5.05% to 6.06%, indicating a stronger influence in the company’s decision-making process. This change could impact the company’s operations and strategic direction, potentially affecting its market positioning and stakeholder interests.
Australian Clinical Labs Limited has announced a change in the address of its share registry office in Sydney, effective from April 14, 2025. The move to a new location at Liberty Place, Castlereagh Street, aims to streamline operations, although telephone numbers and postal addresses remain unchanged. This change reflects ACL’s ongoing efforts to optimize its operational infrastructure, potentially impacting its stakeholders by enhancing service efficiency and accessibility.
Superannuation and Investments HoldCo Pty Ltd has resubmitted a corrected Change in Substantial Holding Form for Australian Clinical Labs Ltd due to minor dependencies discovered in the initial submission. The updated form indicates an increase in voting power from 5.05% to 6.06%, reflecting a significant change in the company’s shareholder structure, which could impact its governance and strategic decisions.
Australian Clinical Labs Ltd has experienced a change in the interests of a substantial holder, Superannuation and Investments HoldCo Pty Ltd. The voting power of this substantial holder has decreased from 10.10% to 6.06%, indicating a significant reduction in their stake in the company. This change may impact the company’s shareholder dynamics and influence its market positioning.
Mitsubishi UFJ Financial Group, Inc. has become a substantial holder in Australian Clinical Labs Ltd, acquiring a significant voting power of 5.06% through various associates. This acquisition indicates a strategic move by Mitsubishi UFJ Financial Group to strengthen its influence within the company, potentially impacting the company’s future decisions and market positioning.
Australian Clinical Labs Ltd has announced that First Sentier Investors RQI Pty Ltd, a subsidiary of Mitsubishi UFJ Financial Group, has become a substantial holder in the company as of April 7, 2025. This development signifies a notable shift in the ownership structure, potentially impacting the company’s strategic direction and stakeholder interests, as First Sentier Investors now holds significant voting power in the company.
Allan Gray Australia Pty Ltd, an investment manager, has increased its voting power in Australian Clinical Labs Ltd from 5.01% to 6.49% as of April 4, 2025. This change in substantial holding indicates a strengthened position for Allan Gray Australia in the company, potentially impacting its influence on corporate decisions and signaling confidence in the company’s future prospects.
Australian Clinical Labs Ltd announced the cessation of 164,164 ordinary fully paid securities due to an on-market buy-back. This move is part of the company’s capital management strategy, potentially impacting its market positioning by optimizing its capital structure and possibly enhancing shareholder value.
Mitsubishi UFJ Financial Group, Inc. has ceased to be a substantial holder in Australian Clinical Labs Ltd as of early April 2025. This change in substantial holding, involving transactions with entities controlled by Morgan Stanley and First Sentier Investors Holdings Pty Ltd, may impact the company’s shareholder structure and influence its market dynamics.
Mitsubishi UFJ Financial Group, Inc. has acquired a substantial holding in Australian Clinical Labs Ltd, with a voting power of over 20% in Morgan Stanley and 100% in First Sentier Investors Holdings Pty Limited. This acquisition involves a significant number of fully paid ordinary shares, indicating a strategic move that could impact the company’s market positioning and influence its future operations.